Predict your next investment

HEALTHCARE | Biotechnology
aprea.com

See what CB Insights has to offer

Founded Year

2003

Stage

IPO | IPO

Total Raised

$112.84M

Date of IPO

10/3/2019

Market Cap

0.09B

Stock Price

5.51

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a biopharmaceutical company focused on the discovery and development of anticancer compounds that reactivate the tumor suppressor protein. p53. The Company's lead drug candidate is APR-246, a small molecule in clinical development for myelodysplastic syndromes (MDS) and high-grade serious ovarian cancer.

Aprea Therapeutics Headquarter Location

535 Boylston Street

Boston, Massachusetts, 02116,

United States

609-510-4718

Latest Aprea Therapeutics News

48 Biggest Movers From Yesterday

Sep 29, 2021

"Following" : "Follow"}} Share: Gainers Gogo Inc. (NASDAQ: GOGO ) shares climbed 37.6% to close at $16.82 on Tuesday after the company raised the long-term financial targets announced during Q4 2020 earnings. Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) climbed 30.7% to close at $6.99 on Tuesday after the company announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe. DatChat, Inc. (NASDAQ: DATS ) gained 26.7% to close at $14.61. United Natural Foods, Inc. (NYSE: UNFI ) rose 23.7% to settle at $46.98 after the company reported better-than-expected Q4 earnings results and issued FY22 EPS guidance above estimates. ABVC BioPharma, Inc. (NASDAQ: ABVC ) surged 22.4% to close at $2.90. Digital Brands Group, Inc. (NASDAQ: DBGI ) shares gained 19.3% to close at $3.52 on Tuesday after the company issued full-year 2022 revenue guidance of $37.5 million to $42.5 million, representing a 350% increase year-over-year. Planet Green Holdings Corp. (NYSE: PLAG ) gained 19.1% to close at $1.37 as Form 4 showed CEO Bin Zhou bought 1.32 million shares at an average price of $2.60 per share. Camber Energy, Inc. (NYSE: CEI ) climbed 18.4% to close at $3.22 after gaining 33% on Monday. Neonode Inc. (NASDAQ: NEON ) rose 18% to settle at $9.30. Neonode announced partnership with MZ Technologie to 'jointly address contactless kiosk and elevator control markets in France.' Schmitt Industries, Inc. (NASDAQ: SMIT ) gained 17.8% to settle at $5.10. Schmitt Industries, last month, reported Q4 sales of $7.86 million. Ondas Holdings Inc. (NASDAQ: ONDS ) climbed 17.5% to close at $9.62. Rallybio Corporation (NASDAQ: RLYB ) gained 13.1% to settle at $15.77. Hallador Energy Company (NASDAQ: HNRG ) surged 12.9% to close at $2.88. Dogness (International) Corporation (NASDAQ: DOGZ ) gained 12.8% to close at $2.83. Alfi, Inc. (NASDAQ: ALF ) rose 12% to close at $7.92 after the company announced a partnership with Vistar Media to enable advertisers to purchase digital out of home campaigns programmatically. Tsakos Energy Navigation Limited (NYSE: TNP ) gained 11.5% to close at $10.06. Frequency Electronics, Inc. (NASDAQ: FEIM ) climbed 11% to settle at $10.60. Frequency Electronics said it won a $17.75 million contract by Office of Naval Research to develop pulsed optically-pumped rubidium atomic frequency standard. Aprea Therapeutics, Inc. (NASDAQ: APRE ) gained 11% to close at $5.15. Aprea Therapeutics recently presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors. ZIVO Bioscience, Inc. (NASDAQ: ZIVO ) climbed 10.2% to close at $4.77 after dropping over 20% on Monday. Forward Industries, Inc. (NASDAQ: FORD ) gained 10% to settle at $2.52. Amplitude, Inc. (NASDAQ: AMPL ) climbed 9.6% to close at $54.80. Amplitude shares opened for trade at $50 per share. Thor Industries, Inc (NYSE: THO ) gained 7.9% to close at $121.75 after the company reported better-than-expected Q4 results. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) gained 7.7% to close at $3.66 after the company announced it signed its first commercial agreement with proptech-focused real estate holding company, MetroSpaces. Evelo Biosciences, Inc. (NASDAQ: EVLO ) gained 7.4% to close at $7.97. Evelo Biosciences recently announced Phase 2 clinical data with EDP1815 in Psoriasis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aprea Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aprea Therapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Aprea Therapeutics Patents

Aprea Therapeutics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2011

6/23/2015

Autoimmune diseases, Neurological disorders, Syndromes, Rheumatology, Rare diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/21/2011

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/23/2015

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Autoimmune diseases, Neurological disorders, Syndromes, Rheumatology, Rare diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Aprea Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aprea Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.